Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study

BACKGROUND: MET exon 14 skipping is an oncogenic driver occurring in 3–4% of non-small cell lung cancer (NSCLC). The MET inhibitor tepotinib has demonstrated clinical efficacy in patients with MET exon 14 skipping NSCLC. Here, we present data from Japanese patients in the Phase II VISION study, eval...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Jpn J Clin Oncol
Main Authors: Sakai, Hiroshi, Morise, Masahiro, Kato, Terufumi, Matsumoto, Shingo, Sakamoto, Tomohiro, Kumagai, Toru, Tokito, Takaaki, Atagi, Shinji, Kozuki, Toshiyuki, Tanaka, Hiroshi, Chikamori, Kenichi, Shinagawa, Naofumi, Takeoka, Hiroaki, Bruns, Rolf, Straub, Josef, Schumacher, Karl Maria, Paik, Paul K
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8326385/
https://ncbi.nlm.nih.gov/pubmed/34037224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyab072
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados